Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-3005 in B-cell Malignancies
NCT07556822Phase 1Recruiting
- Sponsor
- Hengrui
- Start
- Jun 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-3005 in B-cell malignancy, sponsored by Hengrui. Primary endpoints: Incidence of adverse events at 1 year, Maximum tolerated dose at 28 days and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
HRS-3005
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT07556822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07556822.